Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	49.5	86.59	124.33	65.4	193.99	295.18
Cash & Short-Term Investments	49.5	86.59	124.33	65.4	193.99	295.18
Cash Growth	744.37%	-30.36%	90.10%	-66.29%	-34.28%	21.40%
Accounts Receivable	13.65	6.74	16.85	-	1.34	-
Other Receivables	8.86	34.83	76.01	71.18	46.12	108.3
Receivables	22.51	41.57	92.87	71.18	47.46	108.3
Inventory	175.18	194.27	246.9	106.86	50.26	-
Prepaid Expenses	74.31	1.54	8.07	16.89	13	2.31
Other Current Assets	0.27	51.17	133.73	201.37	208.81	155.21
Total Current Assets	321.77	375.13	605.9	461.69	513.52	561.01
Property, Plant & Equipment	6.02	0.04	64.9	88.2	71.05	73.8
Long-Term Deferred Charges	314.82	296.46	167.69	99.67	102	49.67
Other Long-Term Assets	-	-	3.95	3.95	3.95	3.95
Total Assets	642.61	671.62	842.43	653.51	690.52	688.43

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	26.34	8.96	242.57	30.97	23.3	41.39
Accrued Expenses	11.86	12.71	41.19	140.89	66.48	65.76
Current Portion of Long-Term Debt	57.77	-	82.5	62.5	-	-
Current Portion of Leases	2.97	-	13.27	13.37	9.16	7.91
Current Unearned Revenue	-	23.48	147.26	75.41	136.06	95.39
Other Current Liabilities	1.84	7.52	11.15	3.42	1.56	9.22
Total Current Liabilities	100.79	52.66	537.94	326.56	236.57	219.67
Long-Term Debt	-	58.31	66.37	112.9	-	-
Long-Term Leases	2.97	-	29.58	42.71	29.06	36.48
Long-Term Unearned Revenue	-	-	-	-	-	0.54
Other Long-Term Liabilities	-	-	-0	0.01	-	-
Total Liabilities	103.76	110.97	633.89	482.17	265.63	256.69

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2.06	2.06	343.5	6.68	6.17	5.61
Additional Paid-In Capital	1,389	1,386	1,395	1,429	1,294	1,134
Retained Earnings	-862.1	-837.61	-1,540	-1,274	-885.83	-713.31
Comprehensive Income & Other	10.14	10.11	10.23	10.12	10.32	5.16
Shareholders' Equity	538.85	560.65	208.54	171.34	424.89	431.74
Total Liabilities & Equity	642.61	671.62	842.43	653.51	690.52	688.43

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	63.71	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt)	-14.22	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share	-0.69	1.72	-6.85	-723.19	761.51	1328.76
Filing Date Shares Outstanding	20.61	20.61	12.24	0.24	0.22	0.2
Total Common Shares Outstanding	20.61	20.61	12.24	0.24	0.22	0.2
Working Capital	220.98	322.47	67.96	135.14	276.96	341.34
Book Value Per Share	26.15	27.21	17.04	718.44	1930.89	2155.27
Tangible Book Value	538.85	560.65	208.54	171.34	424.89	431.74
Tangible Book Value Per Share	26.15	27.21	17.04	718.44	1930.89	2155.27
Machinery	-	2.75	62.43	61.93	-	43.49

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error